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Abstract
Background:  The bacterial ribosome is a primary target of several classes of antibiotics.
Investigation of the structure of the ribosomal subunits in complex with different antibiotics can
reveal the mode of inhibition of ribosomal protein synthesis. Analysis of the interactions between
antibiotics and the ribosome permits investigation of the specific effect of modifications leading to
antimicrobial resistances.
Streptogramins are unique among the ribosome-targeting antibiotics because they consist of two
components, streptogramins A and B, which act synergistically. Each compound alone exhibits a
weak bacteriostatic activity, whereas the combination can act bactericidal. The streptogramins A
display a prolonged activity that even persists after removal of the drug. However, the mode of
activity of the streptogramins has not yet been fully elucidated, despite a plethora of biochemical
and structural data.
Results: The investigation of the crystal structure of the 50S ribosomal subunit from Deinococcus
radiodurans in complex with the clinically relevant streptogramins quinupristin and dalfopristin
reveals their unique inhibitory mechanism. Quinupristin, a streptogramin B compound, binds in the
ribosomal exit tunnel in a similar manner and position as the macrolides, suggesting a similar
inhibitory mechanism, namely blockage of the ribosomal tunnel. Dalfopristin, the corresponding
streptogramin A compound, binds close to quinupristin directly within the peptidyl transferase
centre affecting both A- and P-site occupation by tRNA molecules.
Conclusions:  The crystal structure indicates that the synergistic effect derives from direct
interaction between both compounds and shared contacts with a single nucleotide, A2062. Upon
binding of the streptogramins, the peptidyl transferase centre undergoes a significant
conformational transition, which leads to a stable, non-productive orientation of the universally
conserved U2585. Mutations of this rRNA base are known to yield dominant lethal phenotypes. It
seems, therefore, plausible to conclude that the conformational change within the peptidyl
transferase centre is mainly responsible for the bactericidal activity of the streptogramins and the
post-antibiotic inhibition of protein synthesis.
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Background
Structural studies of complexes of both small and large
ribosomal subunits with several clinically important anti-
biotics, for example, macrolides, lincosamides or chlo-
ramphenicol [1-3], have significantly advanced our
understanding of the inhibitory action of these antimicro-
bial agents. However, the mechanism of the strepto-
gramin class of antibiotics remains to be fully elucidated
[4].
Streptogramins, which are produced by the genus Strepto-
myces, are divided into two types, A and B, both composed
of macrocyclic lactone rings. Type B streptogramins (SB)
are cyclic hexadepsipeptides whereas type A (SA) are
highly modified cyclopeptides with multiple conjugated
double bonds (Figure 1A). The antimicrobial activity of
streptogramins has been well characterized (reviewed in
[5]), revealing a unique, cooperative action. Alone, each
compound exhibits a moderate bacteriostatic activity, but
in combination the synergistic interplay between the com-
pounds can produce a bactericidal effect [6,7].
Type B streptogramins act on the 50S ribosomal subunit
in a similar fashion as the macrolides and compete for the
same binding site. The SB do not affect the peptidyl trans-
ferase reaction, but inhibit elongation after a few cycles of
peptide bond formation; by analogy with the macrolides,
SB are presumed to bind within the tunnel and block the
path of the nascent polypeptide chain. Consistently,
resistance to both classes of antibiotics arise through com-
mon mechanisms, for example, the resistance against
macrolides, lincosamides and streptogramins B (MLSB)
results from methylation or mutation of A2058.
In contrast, SA  act to prevent protein biosynthesis by
blocking peptide bond formation. Type A streptogramins
apparently do this by interfering with substrate binding at
both acceptor and donor sites of the peptidyl transferase
centre (PTC) [8], thereby inhibiting the peptidyl trans-
ferase reaction directly. Suppression of cell growth persists
for a prolonged lag after removal of the drug [9,10], pre-
sumably due to a stable perturbation of the conformation
of the PTC induced by the binding of SA [11,12].
The most recently approved streptogramin formulation is
Synercid®, a 30:70 combination of dalfopristin (SA) and
quinupristin (SB). The greatly enhanced solubility and
bioavailability of Synercid®, and its excellent activity
against Gram-positive as well as Gram-negative bacteria,
has renewed interest in the medical use of the
streptogramins.
To elucidate the unique cooperative effect of the strepto-
gramin antibiotics, we investigated the structure of the
50S ribosomal subunit from Deinococcus radiodurans
(D50S) in complex with both dalfopristin and quinupris-
tin. The 3.4 Å crystal structure allows the unambiguous
localization of dalfopristin and quinupristin in the core
region of the 50S ribosomal subunit, and enables for the
first time a molecular understanding of the synergistic and
prolonged inhibitory action of this clinically important
class of antibiotics.
Results
Localization and interactions of quinupristin
Quinupristin is bound to 23S rRNA through an extensive
network of hydrophobic interactions involving nucle-
otides of domain II, IV and V, hydrogen bonds between
A2062 and C2586 (nucleotides are numbered according
to the E. coli 23S rRNA sequence throughout the text), and
the macrocyclic ring (Figure 1A, 2), in excellent agreement
with biochemical and mutational data [5,7,12-30] (Figure
1B). Interestingly, the quinuclidinylthio-moiety (Figure
1A) occupies vacant space within the 50S subunit, sug-
gesting that the addition of this moiety to the pristinamy-
cin IA core enhances the bioavailability, but apparently
not the binding properties, of quinupristin.
The binding site of quinupristin is located at the entrance
to the ribosomal tunnel, and does not contact the active
site of the 50S subunit (Figure 3A,3B). This is in agree-
ment with the observation that SB does not affect peptide
bond formation directly, but permits the ribosome to
form a few peptide bonds until further extension of the
nascent chain is prevented by blockage caused by binding
of SB. Quinupristin occupies the same space as the mac-
rolides (Figure 3A), consistent with the strong competi-
tion observed between erythromycin and virginiamycin S
(SB) [25]. In fact, erythromycin can completely abolish SB
binding to the ribosome, illustrating the lower affinity of
the SB. Remarkably, in the Haloarcula marismortui 50S
(H50S)-streptogramin complex no significant binding of
SB has been observed [4]. However, mutations of C2610U
and especially A2058G, both of which are present in H.
marismortui, have been found to confer resistance to SB by
reducing the binding affinity of the drug [31]; therefore,
they provide a plausible explanation for the absence of SB
from the H50S complex.
Localization and interactions of dalfopristin
Dalfopristin is located in a tight pocket within the PTC,
bound by a network of hydrophobic interactions involv-
ing the whole macrocyclic ring as well as the ethanethiol
moiety (Figure 1, 2, 3B). The macrocyclic ring forms
hydrogen bonds with G2505 and G2061, and the only
hydroxyl contained in dalfopristin is hydrogen bonding
to G2505. However, the most prevalent SA  resistance
mechanism is based on the acetylation of this hydroxyl by
virginiamycin acetyltransferase (VatD) [32]. Modification
of the drug would, according to our structure, disrupt theBMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/4
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hydrogen bond with G2505, and prohibit binding of
acetylated SA by steric hindrance. A large number of rRNA
bases within the PTC have been shown to have altered
reactivity in the presence of SA  [19,21], among them
G2058, A2059, A2439, G2505, U2506 and U2585, all of
which directly contribute to the binding of dalfopristin
(Figure 1B), demonstrating the agreement between struc-
tural and biochemical data.
The position of dalfopristin, which largely overlaps with
that of chloramphenicol (Figure 3A), allows a clear inter-
pretation of the inhibitory activity. Dalfopristin interferes
Interactions of streptogramins with 23S rRNA Figure 1
Interactions of streptogramins with 23S rRNA. (A) Chemical structure of quinupristin and dalfopristin. The hydrogen 
bonds towards 23S rRNA nucleotides are indicated. (B) Overview of the nucleotides involved in binding in comparison with 
those indicated by various biochemical and genetic experiments [5, 7, 12-30]. Both images contain numbering for E. coli (in 
green) and for D. radiodurans (in red). The sequence itself corresponds to 23S rRNA of D. radiodurans. All other images use 
numbering according to E. coli.BMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/4
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Structure of dalfopristin and quinupristin within the PTC Figure 2
Structure of dalfopristin and quinupristin within the PTC. To facilitate visualization of the interactions of dalfopristin 
and quinupristin with 23S rRNA, rRNA bases not involved in binding have been omitted. (A) Local environment of dalfopristin 
(in orange). A2062 is highlighted in purple; nucleotides, which are interacting through hydrogen bonds with either dalfopristin 
or quinupristin, are shown in dark blue. (B) Local environment of quinupristin (in green). Colours are as in (A). (C) Stereo 
view of the electron density map of quinupristin (in green) and dalfopristin (in orange). Both compounds have been omitted 
during calculation of the sigmaA weighted difference map, which is contoured at 1.5σ. (D) Stereo representation of dalfopris-
tin and quinupristin and their local environment. Colours as in (A).BMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/4
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with positioning of A- and P-site substrates (Figure 3A),
although the CCA-end of tRNA might be flexible enough
to bind unproductively even in the presence of SA. But,
once the P-site is occupied, binding of dalfopristin to the
ribosome will be suppressed, thus explaining why ribos-
omes actively engaged in protein synthesis are not suscep-
tible to SA (reviewed in [5]). The loss of flexibility of the
CCA-end in the P-site concomitant with nascent chain
extension [33] might enhance this effect, since the effec-
tiveness of SA decreases as the number of amino acids
attached to the P-site tRNA increases [30].
Discussion
Synergism
Synergistic binding of quinupristin and dalfopristin is
presumably facilitated by strong hydrophobic interac-
tions existing between both streptogramins, which lead to
a significant reduction of their solvent accessible surface.
Additionally, both compounds share contacts with a sin-
gle nucleotide, A2062, through hydrophobic interactions
as well as hydrogen bonds. Biochemical data implicate
A2062 as undergoing conformational changes induced by
streptogramin binding [16,20]. When ribosomes were
incubated with SA and SB, the base of A2062, which was
protected by SB alone, became accessible to dimethyl sul-
phate, suggesting that the conformational alterations of
A2062 were induced by SA [16].
This proposal is further supported by the crystal structure
of H50S, which contains two alternating conformations
of A2062 [4]. In the complex of H50S with virginiamycin
M (SA), A2062 also appears to have undergone a confor-
mational change, being rotated by ~90° compared with
the prevalent orientation found in the native structure of
H50S. But, as Hansen et al. (2003) [4] concluded, the con-
formational change of A2062 does not explain the post-
antibiotic effect of SA, since tRNA or substrate analogues
bound to 50S induce a similar conformational change. In
Comparison of antibiotic binding sites Figure 3
Comparison of antibiotic binding sites. (A) To visualize the relative orientations of different classes of antibiotics and 
substrates compared with dalfopristin and quinupristin, several structures have been aligned and overlaid: clindamycin (PDB 
entry 1JZX), erythromycin (1JZY), chloramphenicol (1K01) and CC-Puromycin molecules in A- (A-CCPuro) and P-site (P-
CCPuro). CC-Puromycin coordinates were taken from Bashan et al. (2003) [40]. (B) Overview of the binding sites of quinu-
pristin and dalfopristin within the 50S ribosomal subunit, in relation to the P-site tRNA and the ribosomal exit tunnel (high-
lighted in gold).BMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/4
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the native structure of D50S [34], A2062 obtains an orien-
tation similar to the one observed in the H50S strepto-
gramin complex (Figure 4A), but is rotated by ~15° in the
D50S streptogramin complex to prevent steric clashes
with SB and enable simultaneous accommodation of both
SA and SB. In this orientation, A2062 stacks between quin-
upristin and the macrocyclic ring of dalfopristin, such that
any modification will severely affect the binding of both
compounds. Mutations of A2062 are hence among the
very few 23S rRNA modifications giving rise to both SA
and SB resistance [28]. The movement also affects the local
environment, such that A2058 and A2060 are slightly dis-
placed compared with the native structure (Figure 4A),
Conformation of the PTC Figure 4
Conformation of the PTC. (A) Different orientations of A2062 and its local environment for native D50S (purple), for the 
complex with Synercid® (blue) and for the H50S streptogramin complex (yellow). (B) Comparison of the position of dalfopris-
tin in D50S (orange) with the position of virginiamycin M in H50S (light green), and the corresponding folds of 23S rRNA in the 
vicinity of U2585 (in blue for D50S and in yellow for H50S). (C) Structure and electron density around U2585. For compari-
son, the orientation of U2585 in the native D50S structure is also shown. The electron density is a sigmaA weighted difference 
map omitting the whole peptidyl-transferase ring from the calculation. (D) Local structure around U2585 overlaid with the 
native structure; putative hydrogen bonds of U2585 in its new orientation are indicated. (E) Approximate energy profile 
derived from modelling intermediate conformations, units being arbitrary. N indicates the energy of the native conformation 
and S the one of the complex with Synercid®.BMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/4
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which might contribute to the suppression of MLSB resist-
ance by the presence of SA [11].
The most remarkable conformational changes induced
within the PTC upon binding of dalfopristin are the alter-
ations in the vicinity of U2585 (Figure 4B,4C,4D). This
nucleotide, which points towards the tunnel in the native
structure, appears to be rotated by about 180° to point in
the opposite direction when the streptogramins are
bound. This enables U2585 to form hydrogen bonds with
C2606 and G2588 (Figure 4D), which should lead to a
fairly stable alteration of the PTC.
To gain insight into the stability of this specific rRNA con-
formation, we performed a simple simulation by model-
ling a number of intermediates connecting the native and
the streptogramin induced conformation of the region
around U2585. Assuming that the transition does not
induce large-range perturbations of 23S rRNA, the tight-
ness of the region allows a single trajectory, which
requires only moderate movements of A2439 to permit
the continuous rotation of U2585 by 180°. Calculating
the energy of each intermediate conformation yields a
qualitative picture of the energy profile, showing that the
transition requires the passage through an energy barrier
(Figure 4E), to and from the native and streptogramin
bound structures, which have essentially the same energy
state. Binding of dalfopristin is obviously sufficient to
force the native conformation of U2585 through the
energy barrier to the alternate conformation, and sponta-
neous reversal of this transition will be comparably slow.
This is in agreement with the observation that recovery of
ribosomal activity after removal of SA is followed by a pro-
longed lag [9,10], suggesting that the post-antibiotic effect
of SA can be attributed exclusively to the conformational
change in U2585. Preliminary data of a complex of D50S
with the SA mikamycin A alone showed the same reorien-
tation of U2585 (data not shown), which confirms that
the conformational change is neither unique for dalfo-
pristin nor dependent on the presence of SB.
Although inversion of the orientation of U2585 appears
to be most crucial for the activity of SA, the structure of the
H50S-streptogramin complex [4] shows no significant
conformational change in U2585. This correlates with the
peculiar differences observed in the footprinting pattern
of streptogramins on eubacterial and archaeal ribosomes
[21], and suggests that these antibiotics might exert a
different inhibitory mechanism between archea and
eubacteria.
Implications on peptide bond formation
The universally conserved nucleotide U2585 has been
implicated in the positioning of P-site substrates by vari-
ous biochemical experiments, and mutations of U2585
have been shown to yield a lethal phenotype [35-39]. The
recent structures of A- and P-site substrates in complex
with D50S [40] or H50S [41] placed U2585 in the direct
vicinity of the 3' adenosine of the substrates and its
attached amino acid (or mimics thereof). The proposed
mechanism for peptide bond formation, based on the
local two-fold symmetry inside the PTC, also suggests a
direct interaction of the terminal adenosine of P-site tRNA
with U2585 and assigns a pivotal role for the rotary
motion during peptide bond formation to this nucleotide
[42]. The correct conformation of U2585 is hence essen-
tial for proper positioning of the substrate in the P-site
[35-39], which is a prerequisite for the formation of a
functional 70S initiation complex. The streptogramin
induced conformation of U2585 should, therefore,
severely affect the proper positioning of the 3' end of the
P-site-bound tRNA, in agreement with biochemical data
[16]. Conversely, interactions between U2585 and the P-
site substrate might well stabilize the native conformation
and hence suppress the conformational change required
for SA binding, contributing to the poor inhibition by SA
of ribosomes engaged in protein synthesis.
Conclusions
The structural studies of the 50S ribosomal subunit from
Deinococcus radiodurans in complex with the strepto-
gramins dalfopristin and quinupristin provides a first
glance at the synergistic inhibition of protein synthesis.
The bactericidal activity of the streptogramins can at least
partially be attributed to the induction of the conforma-
tional change of the universally conserved nucleotide
U2585. The altered conformation of U2585 has been
shown to be stabilized by hydrogen bonds, leading to a
rather stable distortion of the PTC. Therefore, it is likely
that the conformational change is also responsible for the
prolonged activity of SA, which can persist for an extended
period after removal of the drug. The synergistic inhibi-
tion appears to be a direct consequence of interactions
between the two streptogramin components, but the fixa-
tion of A2062 in an orientation permitting simultaneous
binding of both compounds contributes significantly to
the synergistic activity.
Methods
Base and amino acid numbering
Nucleotides named (ACGU)1234 are numbered accord-
ing to the 23S rRNA sequence from E. coli to permit a
direct comparison with biochemical data. Translation
tables converting D. radiodurans to E. coli to H. marismortui
are available from the authors or at http://www.ribow
orld.com/nuctrans/. 23S rRNA sequence alignments were
based on the 2D-structure diagrams obtained from Can-
none et al. (2002) [43].BMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/4
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Crystallization
Crystals of the 50S ribosomal subunit were obtained as
previously described by Harms et al. (2001) [34]. Co-crys-
tallization was carried out in the presence of four-fold
excesses of dalfopristin and a 10-fold excess of
quinupristin.
X-ray diffraction
Data were collected at 85 K from shock-frozen crystals
with synchrotron radiation beam at ID19 at Argonne Pho-
ton Source/Argonne National Laboratory (APS/ANL) and
ID14/2, ID14/4 at the European Synchrotron Radiation
Facility/European Molecular Biology Laboratory (ESRF/
EMBL). Data were recorded on ADSC-Quantum 4 or APS-
CCD detectors and processed with HKL2000 [44] and the
CCP4 suite [45]. See Table 1 for data statistics.
Localization and refinement
The native structure of the 50S subunit was refined against
the structure factor amplitudes of the 50S antibiotic com-
plexes, using rigid body refinement as implemented in
CNS [46]. For the calculation of the free R-factor, 5% of
the data were omitted during refinement. The positions of
the antibiotics were readily determined from sigmaA
weighted difference maps (Figure 2C). The quality of the
difference maps revealed unambiguously the position and
orientation of the ligands. Since no structural model of
quinupristin was available, virginiamycin S was used as an
initial model; the quinuclidinylthio-moiety was added
manually and subsequently minimized. The agreement
between the initial model and the density was sufficient to
assume that the conformation of the macrocyclic ring of
quinupristin and virginiamycin S were identical. The
placement of the quinuclidinylthio-moiety is unambigu-
ous; however, the density for this moiety is considerably
weaker (invisible contouring higher than 2.0σ) than the
density of the core of the quinupristin structure (still visi-
ble beyond 3.5σ) (Figure 2C). Further refinement was car-
ried out using CNS  [46]. See Table 1 for refinement
statistics.
Coordinates and figures
Three-dimensional figures were produced with Ribbons
[47]. The ribosome-ligand interactions were originally
determined with LIGPLOT [48], but for sake of clarity rep-
resented in a sketched manner. Final coordinates have
been deposited in the Protein Data Bank [49] under acces-
sion number 1SM1.
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